ArticleNeuro-oncology2020
Molecular correlates of cerebellar mutism syndrome in medulloblastoma.
Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Pre-operative and intra-operative risk factors of post-operative cerebellar mutism syndrome in pediatric patients undergoing posterior fossa tumor surgery: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Cerebellar mutism syndrome caused by bilateral cerebellar hemorrhage in adults: a case report and review of the literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Questions and answers in the management of children with medulloblastoma over the time. How did we get here? A systematic review.Frontiers in oncology · 2023Pooled it
- Development and validation of a preoperative MRI-based predictive model for cerebellar mutism syndrome in pediatric posterior fossa tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Neurosurgical practice and its influence on postoperative paediatric cerebellar mutism syndrome-the Alder Hey experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Long-Term Outcomes Associated With Posterior Fossa Syndrome in Survivors of Childhood Medulloblastoma.JAMA network open · 2026Article
- Fractal dimension as a predictive biomarker for tumor grade and cerebellar mutism syndrome in pediatric posterior fossa tumors.Quantitative imaging in medicine and surgery · 2025Article
- Interobserver variability in assessing preoperative imaging biomarkers for cerebellar mutism syndrome: a multiobserver pilot study.Pediatric radiology · 2025Article
- A predictive model for cerebellar mutism syndrome based on lesion map in children with medulloblastoma.European radiology · 2025Article
- Integrating Radiomics and Lesion Mapping for Cerebellar Mutism Syndrome Prediction.Children (Basel, Switzerland) · 2025Article
- Pediatric CNS tumors: Overview and treatment paradigms.Seminars in pediatric neurology · 2025Review
- Postoperative word-finding difficulties in children with posterior fossa tumours: a crosslinguistic European cohort study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Medical management of cerebellar mutism syndrome at a quaternary children's hospital.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures.Cancer cell · 2024Article
- Postoperative cerebellar mutism syndrome is an acquired autism-like network disturbance.Neuro-oncology · 2024Article
- National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Cerebellar Mutism Syndrome and Dentato-Thalamo-Cortical Tract Disruption in Diffusion Tractography Following Surgery for Medulloblastoma.Radiology · 2024Article
- Application of the Rotterdam postoperative cerebellar mutism syndrome prediction model in patients undergoing surgery for medulloblastoma in a single institution.Journal of neurosurgery. Pediatrics · 2024Article
- Predictors of postoperative complications and functional outcomes in pediatric patients with surgically treated fourth ventricle tumors.Acta neurochirurgica · 2023Article
- Cerebellar mutism is linked to midbrain volatility and desynchronization from speech cortices.Brain : a journal of neurology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebellar mutism syndrome (CMS) is a common complication following resection of posterior fossa tumors, most commonly after surgery for medulloblastoma. Medulloblastoma subgroups have historically been treated as a single entity when assessing CMS risk; however, recent studies highlighting their clinical heterogeneity suggest the need for subgroup-specific analysis. Here, we examine a large international multicenter cohort of molecularly characterized medulloblastoma patients to assess predictors of CMS.
methodsWe assembled a cohort of 370 molecularly characterized medulloblastoma subjects with available neuroimaging from 5 sites globally, including Great Ormond Street Hospital, Christian Medical College and Hospital, the Hospital for Sick Children, King Hussein Cancer Center, and Lucile Packard Children's Hospital. Age at diagnosis, sex, tumor volume, and CMS development were assessed in addition to molecular subgroup.
resultsOverall, 23.8% of patients developed CMS. CMS patients were younger (mean difference -2.05 years ± 0.50, P = 0.0218) and had larger tumors (mean difference 10.25 cm3 ± 4.60, P = 0.0010) that were more often midline (odds ratio [OR] = 5.72, P < 0.0001). In a multivariable analysis adjusting for age, sex, midline location, and tumor volume, Wingless (adjusted OR = 4.91, P = 0.0063), Group 3 (adjusted OR = 5.56, P = 0.0022), and Group 4 (adjusted OR = 8.57 P = 9.1 × 10-5) tumors were found to be independently associated with higher risk of CMS compared with sonic hedgehog tumors.
conclusionsMedulloblastoma subgroup is a very strong predictor of CMS development, independent of tumor volume and midline location. These findings have significant implications for management of both the tumor and CMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.